Gomez J.,Rovira i Virgili University |
Gomez J.,Spanish Biomedical Research Center In Diabetes And Assoc Metabolic Disorders |
Brezmes J.,Rovira i Virgili University |
Brezmes J.,Spanish Biomedical Research Center In Diabetes And Assoc Metabolic Disorders |
And 11 more authors.
Analytical and Bioanalytical Chemistry | Year: 2014
One of the main challenges in nuclear magnetic resonance (NMR) metabolomics is to obtain valuable metabolic information from large datasets of raw NMR spectra in a high throughput, automatic, and reproducible way. To date, established software packages used to match and quantify metabolites in NMR spectra remain mostly manually operated, leading to low resolution results and subject to inconsistencies not attributable to the NMR technique itself. Here, we introduce a new software package, called Dolphin, able to automatically quantify a set of target metabolites in multiple sample measurements using an approach based on 1D and 2D NMR techniques to overcome the inherent limitations of 1D 1H-NMR spectra in metabolomics. Dolphin takes advantage of the 2D J-resolved NMR spectroscopy signal dispersion to avoid inconsistencies in signal position detection, enhancing the reliability and confidence in metabolite matching. Furthermore, in order to improve accuracy in quantification, Dolphin uses 2D NMR spectra to obtain additional information on all neighboring signals surrounding the target metabolite. We have compared the targeted profiling results of Dolphin, recorded from standard biological mixtures, with those of two well established approaches in NMR metabolomics. Overall, Dolphin produced more accurate results with the added advantage of being a fully automated and high throughput processing package. © 2014 Springer-Verlag Berlin Heidelberg. Source
Soria B.,Andalusian Center for Molecular Biology and Regenerative Medicine |
Soria B.,Spanish Biomedical Research Center In Diabetes And Assoc Metabolic Disorders |
Gauthier B.R.,Andalusian Center for Molecular Biology and Regenerative Medicine |
Martin F.,Andalusian Center for Molecular Biology and Regenerative Medicine |
And 9 more authors.
Expert Opinion on Biological Therapy | Year: 2015
Introduction: Tremendous progress has been made in generating insulin-producing cells from pluripotent stem cells. The best outcome of the refined protocols became apparent in the first clinical trial announced by ViaCyte, based on the implantation of pancreatic progenitors that would further mature into functional insulin-producing cells inside the patients body.Areas covered: Several groups, including ours, have contributed to improve strategies to generate insulin-producing cells. Of note, the latest results have gained a substantial amount of interest as a method to create a potentially functional and limitless supply of β-cell to revert diabetes mellitus. This review analyzes the accomplishments that have taken place over the last few decades, summarizes the state-of-art methods for β-cell replacement therapies based on the differentiation of embryonic stem cells into glucose-responsive and insulin-producing cells in a dish and discusses alternative approaches to obtain new sources of insulin-producing cells.Expert opinion: Undoubtedly, recent events preface the beginning of a new era in diabetes therapy. However, in our opinion, a number of significant hurdles still stand in the way of clinical application. We believe that the combination of the private and public sectors will accelerate the process of obtaining the desired safe and functional β-cell surrogates. © 2015 Informa UK, Ltd. Source